Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricardo Dent

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Clinical Epidemiology|January 20, 2022
Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection FractionQuinn S Wells, Eric Farber-Eger, Loren Lipworth, et al.
Cardiovascular Drugs and Therapy|June 1, 2016
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Springerplus|April 12, 2016
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingRicardo Dent, Raju Joshi, C Stephen Djedjos, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 8, 2011
Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy studyJacques P Brown, David W Dempster, Beiying Ding, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Cardiovascular Drugs and Therapy|August 4, 2018
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension StudiesLeslie Cho, Ricardo Dent, Erik S G Stroes, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Atherosclerosis|December 31, 2015
Identification and management of patients with statin-associated symptoms in clinical practice: A clinician surveyG Kees Hovingh, Shravanthi R Gandra, Jan McKendrick, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Clinical Epidemiology|January 20, 2022
Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection FractionQuinn S Wells, Eric Farber-Eger, Loren Lipworth, et al.
Cardiovascular Drugs and Therapy|June 1, 2016
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Springerplus|April 12, 2016
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingRicardo Dent, Raju Joshi, C Stephen Djedjos, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 8, 2011
Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy studyJacques P Brown, David W Dempster, Beiying Ding, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Cardiovascular Drugs and Therapy|August 4, 2018
Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension StudiesLeslie Cho, Ricardo Dent, Erik S G Stroes, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Atherosclerosis|December 31, 2015
Identification and management of patients with statin-associated symptoms in clinical practice: A clinician surveyG Kees Hovingh, Shravanthi R Gandra, Jan McKendrick, et al.
Pageof 4